SEOUL, South Korea – July 30, 2025 – Dx&Vx (DXVX) has signed its first global out-licensing agreement, a deal valued at approximately USD 220 million, with a U.S.-based biotech company for its proprietary mRNA-based cancer vaccine. This landmark agreement also includes potential post-commercialization sales milestones exceeding USD 940 million.
Under the terms, DXVX retains leadership of R&D, including preclinical and clinical trials (Phase 1-3) and production, while the partner will manage global regulatory approvals and sales.
The licensed mRNA cancer vaccine has shown superior anticancer efficacy in preclinical studies compared to competitors and utilizes DXVX’s unique long-term ambient storage mRNA vaccine platform technology.
Kevin Kwon, CEO of DXVX, expressed pleasure with the agreement, noting it acknowledges their technological strength and could positively impact other ongoing licensing discussions. DXVX’s pipeline also includes other mRNA platforms, an oral anti-obesity therapeutic, and a peptide-based cancer vaccine.
Source:
https://www.prnewswire.com/news-releases/dxvx-signs-usd-220-million-co-development-and-license-agreement-for-mrna-cancer-vaccine-with-us-biotech-company-302517318.html
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
